Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) Receives $3.86 Average Price Target from Analysts

by · The Markets Daily

Shares of Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH – Get Free Report) have earned an average rating of “Moderate Buy” from the nine brokerages that are presently covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, seven have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month price target among brokerages that have covered the stock in the last year is $3.8571.

RVPH has been the topic of a number of research reports. HC Wainwright reaffirmed a “buy” rating and set a $4.00 target price on shares of Reviva Pharmaceuticals in a research report on Tuesday, December 23rd. Chardan Capital raised shares of Reviva Pharmaceuticals to a “strong-buy” rating in a research report on Wednesday, November 19th. Wall Street Zen raised Reviva Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, December 27th. Benchmark lowered their price objective on Reviva Pharmaceuticals from $14.00 to $7.00 and set a “speculative buy” rating on the stock in a research report on Monday, September 15th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Reviva Pharmaceuticals in a research note on Wednesday, October 8th.

Get Our Latest Research Report on RVPH

Hedge Funds Weigh In On Reviva Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in the company. NewEdge Advisors LLC acquired a new position in shares of Reviva Pharmaceuticals in the 1st quarter worth approximately $58,000. Geode Capital Management LLC boosted its stake in Reviva Pharmaceuticals by 6.9% in the second quarter. Geode Capital Management LLC now owns 448,202 shares of the company’s stock worth $171,000 after purchasing an additional 29,063 shares in the last quarter. Persistent Asset Partners Ltd grew its holdings in shares of Reviva Pharmaceuticals by 300.0% during the second quarter. Persistent Asset Partners Ltd now owns 641,174 shares of the company’s stock worth $244,000 after purchasing an additional 480,864 shares during the last quarter. XTX Topco Ltd acquired a new stake in shares of Reviva Pharmaceuticals in the second quarter valued at $31,000. Finally, Armistice Capital LLC bought a new position in shares of Reviva Pharmaceuticals in the second quarter valued at about $1,026,000. 63.18% of the stock is owned by institutional investors.

Reviva Pharmaceuticals Stock Performance

Shares of RVPH stock opened at $0.31 on Friday. The stock’s 50 day simple moving average is $0.52 and its 200 day simple moving average is $0.49. Reviva Pharmaceuticals has a twelve month low of $0.25 and a twelve month high of $2.17. The company has a market capitalization of $35.67 million, a price-to-earnings ratio of -0.67 and a beta of 0.08.

Reviva Pharmaceuticals (NASDAQ:RVPH – Get Free Report) last announced its quarterly earnings results on Thursday, November 13th. The company reported ($0.06) EPS for the quarter, beating the consensus estimate of ($0.11) by $0.05. On average, analysts forecast that Reviva Pharmaceuticals will post -0.97 EPS for the current fiscal year.

Reviva Pharmaceuticals Company Profile

(Get Free Report)

Reviva Pharmaceuticals, Inc (NASDAQ: RVPH) is a specialty pharmaceutical company focused on the acquisition, development and commercialization of prescription drug products in the United States and select international markets. Founded in 2002 and headquartered in Coral Gables, Florida, Reviva targets under-promoted, off-patent pharmaceuticals for which novel dosage forms can enhance patient compliance and therapeutic outcomes.

The company’s core activities include the identification of FDA-approved drug candidates, formulation development to address niche or underserved patient populations—such as pediatric and orphan indications—and supporting regulatory filings.

Further Reading